28,818 Shares of Twist Bioscience Corporation $TWST Bought by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. purchased a new position in Twist Bioscience Corporation (NASDAQ:TWST) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 28,818 shares of the company’s stock, valued at approximately $5,569,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TWST. Diversify Advisory Services LLC purchased a new stake in Twist Bioscience during the 3rd quarter valued at about $501,000. Prime Capital Investment Advisors LLC acquired a new stake in Twist Bioscience in the 3rd quarter valued at about $260,000. Abel Hall LLC raised its holdings in Twist Bioscience by 3.6% in the 3rd quarter. Abel Hall LLC now owns 5,514 shares of the company’s stock valued at $1,066,000 after acquiring an additional 191 shares during the last quarter. SteelPeak Wealth LLC lifted its stake in Twist Bioscience by 8.2% in the 3rd quarter. SteelPeak Wealth LLC now owns 6,143 shares of the company’s stock worth $1,187,000 after purchasing an additional 466 shares in the last quarter. Finally, Triasima Portfolio Management inc. purchased a new position in Twist Bioscience in the 3rd quarter worth approximately $652,000.

Insider Buying and Selling at Twist Bioscience

In related news, SVP Paula Green sold 10,088 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total value of $1,905,421.44. Following the transaction, the senior vice president directly owned 106,632 shares in the company, valued at approximately $20,140,652.16. This represents a 8.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Robert F. Werner sold 1,482 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $279,920.16. Following the completion of the transaction, the chief accounting officer owned 42,917 shares in the company, valued at $8,106,162.96. This represents a 3.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 601,920 shares of company stock worth $93,768,202. Insiders own 3.08% of the company’s stock.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $139.92 on Friday. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $219.71. The stock has a market cap of $8.77 billion, a P/E ratio of -63.03 and a beta of 2.19. The company has a 50-day moving average price of $149.89 and a 200 day moving average price of $103.13. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The firm had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. Twist Bioscience’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period last year, the firm earned $0.33 earnings per share. Sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TWST. BWS Financial restated a “sell” rating and set a $45.00 target price on shares of Twist Bioscience in a report on Friday, September 18th. TD Cowen increased their price target on Twist Bioscience from $115.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Barclays increased their price target on Twist Bioscience from $112.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Piper Sandler lifted their price objective on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Finally, Evercore lowered Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective on the stock. in a research note on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $143.67.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.